1.A preliminary study of platelet hyperactivity in the chronic indeterminate phase of Chagas’ disease
Flavio Rojas Castillejos ; Laura Perez-Campos Mayoral ; Gabriel Mayoral Andrade ; Maria Teresa Hernandez-Huerta ; Socorro Pina-Canseco ; Ruth Martinez Cruz ; Efrain Herrera Colmenares ; Eduardo Perez-Campos Mayoral ; Paz Maria Salazar ; Martha Bucio Torres ; Margarita Cabrera Bravo ; Margarito Martinez Cruz ; Carlos Matí ; as Cervantes ; Roxana Diaz Albarraz ; Joel Lopez Matias ; Gabriela Ines Rios Arias ; Gema Hrnandez Bernardino ; Ernesto Perez Matus ; Rosalinda Mendez Trujillo ; Luis Manuel Sanchez Navarro ; Alma Dolores Perez Santiago ; Eduardo Perez Campos
Tropical Biomedicine 2018;35(3):678-683
The chronic indeterminate phase of Chagas’ disease is asymptomatic despite
positive test results for antibodies specific to Trypanosoma cruzi. CD62P-APC (P-selectin)
and PAC-1 FITC (GpIIb/IIIa) may improve diagnosis as biomarkers of platelet activity. Nine
asymptomatic seropositive subjects, previously untreated, were selected from a blood bank
within a year of Chagas’ disease detection, in addition to a control group of four. All subjects
were evaluated by flow cytometry for CD62P, PAC-1 and CD41, and in a complementary
study, by Tissue Doppler Echocardiography for isovolumic relaxation times (IVRT) and E/A
ratios. The subjects were classified as positive or negative for CD62P and PAC-1 by a cut off
obtained from their mean±2SD. For IVRT and E/A ratios, cut offs were obtained from the
American Society of Echocardiography and the European Association of Cardiovascular
Imaging recommendations. Fisher’s exact test was used for associated findings. Pre-test and
post-test probability, sensitivity, specificity, positive and negative predictive values and
likelihood ratios were calculated. Abnormalities were expressed as platelet hyperactivity
and ventricular dysfunction in CD62P, PAC-1, IVRT and E/A ratios. CD62P appears to have
greater sensitivity (0.75) and PAC-1, more accurate specificity (0.75), which may explain
thrombotic events in Chagas’ disease. We recommend the use of CD62P and PAC-1 as biomarkers
of platelet hyperactivity in patients in the chronic indeterminate phase of Chagas’ disease.
Result Analysis
Print
Save
E-mail